The China Mail - US panel weighs authorizing Covid vaccines for youngest children

USD -
AED 3.672981
AFN 62.999984
ALL 82.597888
AMD 368.060083
ANG 1.790403
AOA 916.999878
ARS 1481.256531
AUD 1.451358
AWG 1.80125
AZN 1.68207
BAM 1.71493
BBD 2.014108
BDT 123.249054
BGN 1.69088
BHD 0.377034
BIF 2975.014577
BMD 1
BND 1.293507
BOB 6.925154
BRL 5.189102
BSD 1.000039
BTN 94.490039
BWP 13.589892
BYN 2.900133
BYR 19600
BZD 2.011197
CAD 1.419815
CDF 2267.504195
CHF 0.807303
CLF 0.023428
CLP 922.060241
CNY 6.79815
CNH 6.79833
COP 3447.03
CRC 453.586914
CUC 1
CUP 26.5
CVE 96.684671
CZK 21.2308
DJF 177.720253
DKK 6.541155
DOP 59.466972
DZD 133.187486
EGP 49.201402
ERN 15
ETB 161.218522
EUR 0.87515
FJD 2.24725
FKP 0.757857
GBP 0.754305
GEL 2.644967
GGP 0.757857
GHS 11.31015
GIP 0.757857
GMD 73.000242
GNF 8766.638023
GTQ 7.629344
GYD 209.175084
HKD 7.841989
HNL 26.761891
HRK 6.593901
HTG 130.701074
HUF 309.838968
IDR 17868.95
ILS 2.98755
IMP 0.757857
INR 94.542202
IQD 1309.991977
IRR 1375250.000138
ISK 126.029814
JEP 0.757857
JMD 157.463469
JOD 0.709012
JPY 161.9355
KES 129.501624
KGS 87.45008
KHR 4021.166805
KMF 434.000271
KPW 900.00035
KRW 1541.080284
KWD 0.30956
KYD 0.833333
KZT 485.532407
LAK 22428.570802
LBP 89548.611111
LKR 336.248811
LRD 181.993547
LSL 16.430491
LTL 2.95274
LVL 0.604889
LYD 6.424601
MAD 9.371084
MDL 17.675014
MGA 4255.281837
MKD 53.944432
MMK 2099.649649
MNT 3579.92745
MOP 8.078178
MRU 39.910387
MUR 47.240213
MVR 15.450138
MWK 1734.006734
MXN 17.483585
MYR 4.071199
MZN 63.897811
NAD 16.430635
NGN 1381.869793
NIO 36.800779
NOK 9.918205
NPR 151.185701
NZD 1.769045
OMR 0.384495
PAB 1.000018
PEN 3.414923
PGK 4.390353
PHP 61.197085
PKR 278.074382
PLN 3.75255
PYG 6089.674735
QAR 3.645212
RON 4.588027
RSD 102.697996
RUB 76.998674
RWF 1467.978395
SAR 3.756538
SBD 8.051953
SCR 13.537737
SDG 599.999621
SEK 9.707925
SGD 1.292301
SHP 0.746601
SLE 24.798647
SLL 20969.503664
SOS 571.521265
SRD 37.494501
STD 20697.981008
STN 21.482654
SVC 8.749978
SYP 110.532098
SZL 16.426633
THB 33.25504
TJS 9.269869
TMT 3.5
TND 2.962063
TOP 2.40776
TRY 46.637499
TTD 6.798104
TWD 31.850497
TZS 2625.002971
UAH 44.880508
UGX 3665.2038
UYU 40.238326
UZS 12052.207233
VES 620.752985
VND 26290
VUV 119.179282
WST 2.780883
XAF 575.16627
XAG 0.017174
XAU 0.000249
XCD 2.70255
XCG 1.802247
XDR 0.716371
XOF 575.168792
XPF 104.571381
YER 238.625034
ZAR 16.408991
ZMK 9001.199474
ZMW 18.104658
ZWL 321.999592
  • CMSC

    0.1200

    22.05

    +0.54%

  • CMSD

    0.1300

    21.9

    +0.59%

  • BCC

    -2.2900

    78.73

    -2.91%

  • BTI

    -0.3900

    62.37

    -0.63%

  • NGG

    0.6700

    83.68

    +0.8%

  • RIO

    0.5600

    94.3

    +0.59%

  • BCE

    -0.6450

    22.275

    -2.9%

  • RBGPF

    0.2000

    61.5

    +0.33%

  • GSK

    0.0850

    52.585

    +0.16%

  • RYCEF

    0.0000

    18.75

    0%

  • JRI

    0.0900

    12.88

    +0.7%

  • BP

    0.3450

    37.475

    +0.92%

  • VOD

    -0.1700

    13.72

    -1.24%

  • RELX

    -0.0800

    31.26

    -0.26%

  • AZN

    1.8000

    190.21

    +0.95%

US panel weighs authorizing Covid vaccines for youngest children
US panel weighs authorizing Covid vaccines for youngest children / Photo: © AFP/File

US panel weighs authorizing Covid vaccines for youngest children

After months of anxious wait for some parents, a panel of experts convened by the US Food and Drug Administration will meet Wednesday to weigh recommending Covid vaccines for the nation's youngest children.

Text size:

Children under five are the only age group not yet eligible for Covid immunization in the United States and most other countries. If, as expected, panelists vote in favor of greenlighting the Pfizer and Moderna vaccines, formal authorizations should follow quickly, with the first shots in arms expected by next week.

Ahead of the meeting, the FDA posted its independent analyses of the two drugs, deeming both safe and effective. It also said there was a pressing unmet need to inoculate children in the age group since their rates of hospitalization and death "are higher than among children and adolescents 5-17 years of age."

Both vaccines are based on messenger RNA technology, which delivers genetic code for the coronavirus spike protein to human cells, training the immune system to be ready for when it encounters the real virus.

Pfizer is seeking authorization for three doses at three micrograms given to ages six months through four years, while Moderna has asked for the FDA to approve its vaccine as two doses of a higher 30 micrograms, for ages six months through five years.

They were tested in trials of thousands of children where they were found to have similar levels of mild effects to older age groups and triggered similar levels of antibodies.

Efficacy against infection was higher for Pfizer, with the company placing it at 80 percent compared to Moderna's estimates of 51 percent in the six-month-old to age two group and 37 percent in the two to five years age group.

But the figures are provisional and Moderna is studying adding a third dose later that may increase its figures.

There are some 20 million US children aged four years and under. If the FDA-appointed experts recommend the two vaccines, then the matter will go to another committee convened by the Centers for Disease Control and Prevention for a final say.

White House officials last week said the rollout of millions of shots at pharmacies and doctors' offices could begin as soon as June 21, following the Juneteenth holiday on June 20.

Of the total US Covid deaths, 480 have come in children under five, according to the latest official data.

Obesity, neurological disorders and asthma are associated with increased risk of severe disease, "however, a majority of children hospitalized for Covid-19 have no underlying medical conditions," the FDA said in a document.

Children can also go on to contract multisystem inflammatory syndrome in children (MIS-C), a rare but serious post-viral condition.

Data on long Covid in children is sparse, but the FDA's document cited a national survey in the United Kingdom which found that "among children ages two to 11 years who tested positive for COVID-19, 7.2 percent reported continued symptoms at 12 weeks."

C.Smith--ThChM